Nuvalent, Inc., a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, has appointed Christy Oliger to its Board of Directors. Oliger, who brings over 30 years of experience in the pharmaceutical and biotechnology industry, was previously the Senior Vice President of the Oncology Business Unit at Genentech. Her appointment comes as Nuvalent prepares for potential commercialization of its novel kinase inhibitors in 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.